The study of external aerodynamics of an aircraft carrier is of utmost importance in ensuring the safety of aircraft and pilots during take-off and recovery. The velocity deficit in the forward direction and the downwash together combine to give a sinking effect to the aircraft, along its glideslope path and is known as the ‘burble’ in naval aviation parlance. This phenomenon is primarily responsible for the potential increase in pilot workload on approach to the aircraft carrier. There is little literature in the open domain regarding ways and means to alleviate the burble effect. Unlike in the case of the automobile industry, which has the generic ‘Ahmed body’ and for the frigates/destroyers, for which there is the Simplified Frigate Ship (SFS), on which experiments and validation through CFD could be carried out, by researchers from all over the world, there is no generic Aircraft Carrier model for carrying out experiments and validation of CFD codes. The aim of this study is to define the Generic Aircraft Carrier Model (GAC), as developed at IIT Delhi, and to carry out numerical studies on the GAC and a variant of GAC without the island, BGAC (Baseline GAC), to assess the contribution of the island to the burble behind an Aircraft Carrier. This study gives a quantitative estimation of the effect and contribution of individual components of an Aircraft Carrier (like flight deck, island, etc.) to the burble behind the carrier, and would give a Naval Ship Designer an understanding of the effect of the geometrical configuration of the flight deck and the island on generation of the burble behind the carrier, which could aid the designer in potentially reducing the pilot workload.

priately identify the best treatment has become more important. The purpose of this analysis is to compare the rates of testing among HN patients on two key biomarker tests PD-L1 and HPV status in the US and 5 European (EU5) countries. MethodS: A retrospective medical chart review of patients with HN in the US (n= 606) and EU5 (France, Germany, Italy, Spain, UK; n= 1,000) was conducted between 7/2016 and 6/2017. Physicians randomly selected patient charts currently on an anti-cancer regimen and extracted data on patient demographics, disease status, treatment patterns, and biomarker status. ReSultS: Of the 1,606 HN patients included in this analysis, the US and EU5 had different gender distributions (percent male US: 68%, EU: 81%, p= < 0.01), but similar average ages (mean (SD) US: 62.86 (8.25), EU: 63.32 (8.81) between groups (p= 0.29). When identifying PD-L1 status between the countries, significantly more patients in the EU5 had never been tested (76%, US: 61%, p= < 0.01). Of those who were tested in the US (n= 238) and EU5 (n= 244), 63% of patients in the US were positive compared to only 35% in the EU5 (p= < 0.01). HPV results showed no differences in the testing rate (US: 89%, EU5: 91%, p= 0.54), but of those tested (US: 535, EU5: 908) significantly more HN patients tested HPV positive in the US (26%) than in the EU5 (16%, p= < 0.01). ConCluSionS: As new advanced therapies become available the importance of biomarker testing among HN cancer patients will continue to grow. Understanding the differences in how tests are used as well as patient test results by region is vital in the development and testing process.

No abstract

s139 multiple stakeholders. The program has resulted in high patient satisfaction and adherence , compliance and persistence of the current program . Future studies will be conducted to assess the impact of the program on financial benefits, and other patient safety and quality outcomes.

No abstract